Kazia Therapeutics Reveals Promising Brain Cancer Study
PremiumCompany AnnouncementsKazia Therapeutics Reveals Promising Brain Cancer Study
1M ago
Kazia Therapeutics announces presentation of Phase 1 data on paxalisib
Premium
The Fly
Kazia Therapeutics announces presentation of Phase 1 data on paxalisib
1M ago
Kazia Therapeutics Reveals Hopeful Ovarian Cancer Study
Premium
Company Announcements
Kazia Therapeutics Reveals Hopeful Ovarian Cancer Study
2M ago
Kazia’s Paxalisib Shows Potential in Glioblastoma Trial
PremiumCompany AnnouncementsKazia’s Paxalisib Shows Potential in Glioblastoma Trial
4M ago
Kazia Therapeutics reports results from GBM-AGILE phase II/III study
Premium
The Fly
Kazia Therapeutics reports results from GBM-AGILE phase II/III study
4M ago
Kazia Therapeutics files to sell 1.1M ADSs for holders
Premium
The Fly
Kazia Therapeutics files to sell 1.1M ADSs for holders
5M ago
Kazia Therapeutics’ EVT801 Phase 1 clinical trial completes Phase 1 objectives
PremiumThe FlyKazia Therapeutics’ EVT801 Phase 1 clinical trial completes Phase 1 objectives
6M ago
Kazia Therapeutics licenses paxalisib to Sovargen
Premium
The Fly
Kazia Therapeutics licenses paxalisib to Sovargen
8M ago
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100